-
2001
Emerging role of GLP-1 receptor agonists in the treatment of obesity
Published 2010-07-01“…However, there is a paucity of pharmacologic agents approved for the treatment of obesity, and the use of existing weight loss medications is frequently limited by contraindications, drug interactions, adverse effects, limited coverage by third-party payers, and cost. …”
Get full text
Article -
2002
Herbal Medicines In The Treatment of Psychiatric and Neurological Disorders
Published 2006-04-01“…Conclusion: Herbs may have beneficial effects in variety of psychiatric and neurological disorder; however we must consider their potential side effects and drug-drug interactions.…”
Get full text
Article -
2003
Emerging role of GLP-1 receptor agonists in the treatment of obesity
Published 2010-07-01“…However, there is a paucity of pharmacologic agents approved for the treatment of obesity, and the use of existing weight loss medications is frequently limited by contraindications, drug interactions, adverse effects, limited coverage by third-party payers, and cost. …”
Get full text
Article -
2004
Interactions of naturally occurring compounds with antimicrobials
Published 2023-12-01“…This review presents collected information on natural compounds (terpenes, alkaloids, flavonoids, tannins, sulfoxides, and mycotoxins), of which various drug interactions have been observed. Many of the indicated compounds show synergistic or additive interactions with antibiotics, which suggests their potential for use in antibacterial therapy, reducing the toxicity of the antibiotics used and the risk of further development of bacterial resistance. …”
Get full text
Article -
2005
New class of agents for treatment of hypertension: Focus on direct renin inhibition
Published 2010-10-01“…The blood pressure-lowering effect of aliskiren monotherapy is similar, if not superior, to that of other first-line antihypertensive agents, and is greatly enhanced when aliskiren is combined with various other antihypertensive medications, without any adverse drug interactions. Aliskiren is also an effective and well tolerated therapy in special populations, including diabetic, obese, and elderly hypertensives. …”
Get full text
Article -
2006
A strategy for evaluating potential antiviral resistance to small molecule drugs and application to SARS-CoV-2
Published 2023-01-01“…For each drug target, we determined the drug-interacting virus residues from available structures and the selection pressure of the virus residues from the SARS-CoV-2 genomes. …”
Get full text
Article -
2007
Sotatercept for Pulmonary Arterial Hypertension in the Inpatient Setting
Published 2024-02-01“…Pulmonary arterial hypertension treatment for acute on chronic RV failure can be impacted by end-organ damage, hemodynamic instability, drug interactions, and PAH medications dosage and delivery. …”
Get full text
Article -
2008
Long-term use of rosuvastatin: a critical risk benefit appraisal and comparison with other antihyperlipidemics
Published 2009-08-01“…Its chemical and pharmacokinetic properties (with a low lipophilicity and poor capacity to inhibit cytochrome P450 enzymes) suggest a very limited penetration in extrahepatic tissues with a lower risk of muscle toxicity and unlike metabolically mediated drug–drug interactions. This article reviews the most recent data on the pharmacologic and clinical properties of rosuvastatin, in order to enable the correct use of this statin for the treatment of hypercholesterolemia.Keywords: statin, HMG-CoA reductase, LDL cholesterol, pharmacokinetics, safety…”
Get full text
Article -
2009
Snail protein inhibition by drug repositioning for recurrent breast cancer: an in-silico study
Published 2023-05-01“…Molecular docking and molecular dynamics simulation were performed to examine Snail-drugs interactions. Results: Our docking analysis identified Stivarga and Sorafenib, two antineoplastic drugs, as potential repositioning drugs to treat recurrent breast cancer due to their low free binding energy values. …”
Get full text
Article -
2010
-
2011
Can P-glycoprotein influence the bioavailability of iminosugar-based glucosylceramide synthase inhibitors?
Published 2006“…This question warrants attention given the potential to induce adverse drug interactions or toxicity, if glucosylceramide synthase inhibitors are administered with other P-glycoprotein substrates. …”
Journal article -
2012
Management of erectile dysfunction: barriers faced by general practitioners
Published 2004“…An adequate understanding of how these factors (doctors, patients and drugs) interact can assist in the formulation and implementation of strategies that encourage GPs to identify and manage ED patients.…”
Article -
2013
Appraisal of antiretroviral herbal medicines with proven efficacy: modulation of drug-metabolizing enzymes and permeability glycoprotein activities
Published 2022-10-01“…Phytochemical constituents of the herbal medicinal products with antiretroviral activities were identified, and their potential to mediate pharmacokinetic changes through modulation of drug-metabolizing enzymes and P-glycoprotein was reported. Herb-drug interactions (HDIs) that can result in significant adverse effects were also discussed with documenting the information for the therapeutic utility of these clinically effective antiretroviral herbal medicinal products with potential for development into newer anti-HIV drugs.…”
Get full text
Article -
2014
Formulation of enteric coated microspheres containing pantoprazole
Published 2022-03-01“… Pantoprazole is a first-line proton pump inhibitor drug for the treatment of gastric acid secretion disorders that is known to have minimal side effects and drug interactions. To improve its stability in gastric acid, delayedrelease microspheres containing pantoprazole was prepared by emulsification-solvent evaporation using a polymer-containing mixture of hydroxypropyl cellulose (HPC) and ethyl cellulose (EC), which was then coated by alginate and Eudragit L100. …”
Get full text
Article -
2015
Continuum of Care UNAIDS Fast-Track Targets Evaluation of Patients Living with Human Immunodeficiency Virus Infection
Published 2021-09-01“…A shift towards integrase strand transfer inhibitors, with a higher efficacy, fewer adverse effects, and fewer drug interactions, is observed, which could contribute to the decrease in HIV transmission.…”
Get full text
Article -
2016
The effect of antibacterial and non-antibacterial compounds alone or associated with antifugals upon fungi
Published 2015-07-01“…Thus, the role of combined therapy and the effect of antibiotics upon fungal growth promotion needs to be critically evaluated and understood in order to avoid undesirable drug interactions. With this review we intend discuss the studies that report about antibiotics inhibiting fungal growth, as well as studies describing the synergistic effect of the combined therapy, i.e. associations between antibiotics or other compounds with antifungal drugs. …”
Get full text
Article -
2017
OBJECTIVE AND SUBJECTIVE FACTORS OF MEDICAL DRUG CHOICE
Published 2017-05-01“…Doctors need and are interested in information on the pharmacokinetics and pharmacodynamics of MD, side effects, drug interactions and results of clinical studies. Conclusion. …”
Get full text
Article -
2018
Advances and Challenges of Cannabidiol as an Anti-Seizure Strategy: Preclinical Evidence
Published 2022-12-01“…Here, we present an overview of recent literature pointing out CBD’s pharmacological profile (solubility, metabolism, drug-drug interactions, etc.,), CBD’s interactions with multiple molecular targets as well as advances in preclinical research concerning its anti-seizure effect on both acute seizure models and chronic models of epilepsy. …”
Get full text
Article -
2019
Drug-Disease Severity and Target-Disease Severity Interaction Networks in COVID-19 Patients
Published 2022-08-01“…Drug interactions with other drugs are a well-known phenomenon. …”
Get full text
Article -
2020
Farnesoid X Receptor Agonists: A Promising Therapeutic Strategy for Gastrointestinal Diseases
Published 2024-01-01“…We also highlight the safety, adverse effects, and potential drug interactions associated with FXR agonists. While these agents have demonstrated efficacy in improving liver function, reducing hepatic steatosis, and improving histological endpoints in primary biliary cholangitis and nonalcoholic fatty liver disease, further research is needed to determine their long-term safety and effectiveness in other GI diseases, such as inflammatory bowel disease, alcohol-related liver disease, and primary sclerosing cholangitis. …”
Get full text
Article